deaths (OS)progression or deaths (PFS)RFS/DFS

mML - L1 - BRAF wild metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF wild

versus pembrolizumab alone
atezolizumab plus cometinib vs. pembrolizumab alone 1 certainty unassessable+6% certainty unassessable+15%-